Ring Therapeutics
Cambridge, United States· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Total funding raised: $86.5M
Overview
A platform company developing a novel gene therapy and vaccine delivery system based on commensal anelloviruses.
Genetic DiseasesOncologyInfectious Diseases
Technology Platform
Symbiotic Platform that engineers commensal anelloviruses from the human virome into programmable, re-dosable vectors for gene therapy and vaccines.
Funding History
1Total raised:$86.5M
Series C$86.5M
Opportunities
Potential to unlock re-dosable gene therapy and create a new, tolerated delivery standard, addressing a multi-billion dollar market limitation.
Risk Factors
High technical and biological risk in proving that engineered anelloviruses are safe, manufacturable, and efficacious in humans, a completely unproven approach.
Competitive Landscape
A first-mover in commensal virus vectors, facing indirect competition from all established viral vector and non-viral delivery technologies in gene therapy.